HighTide Therapeutics (HKSE:02511) Price-to-Tangible-Book : 4.10 (As of May. 20, 2024)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Price-to-Tangible-Book?

As of today (2024-05-20), HighTide Therapeutics's share price is HK$6.12. HighTide Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$1.49. Hence, HighTide Therapeutics's Price to Tangible Book Ratio of today is 4.10.

The historical rank and industry rank for HighTide Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

HKSE:02511' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.11 Med: 8.68 Max: 8.68
Current: 4.11

During the past 3 years, HighTide Therapeutics's highest Price to Tangible Book Ratio was 8.68. The lowest was 4.11. And the median was 8.68.

HKSE:02511's Price-to-Tangible-Book is ranked worse than
67.4% of 1230 companies
in the Biotechnology industry
Industry Median: 2.81 vs HKSE:02511: 4.11

A closely related ratio is called PB Ratio. As of today, HighTide Therapeutics's share price is HK$6.12. HighTide Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$1.49. Hence, HighTide Therapeutics's P/B Ratio of today is 4.10.

HighTide Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for HighTide Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Price-to-Tangible-Book Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

8.68

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	-	-	-	-	8.68

Competitive Comparison of HighTide Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, HighTide Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Price-to-Tangible-Book falls into.

HighTide Therapeutics Price-to-Tangible-Book Calculation

HighTide Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	6.12	/	1.493
	=	4.10

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

HighTide Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines